Celgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up what could be a new blockbuster for the soon-to-be acquired Celgene.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh